Adagio medical, inc. announces completion of enrollment for fulcrum-vt pivotal clinical trial evaluating ultra-low temperature cryoablation for ventricular tachycardia

Laguna hills, calif.--(business wire)--adagio medical holdings, inc. (nasdaq: adgm) (“adagio” or “the company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the completion of enrollment of the fulcrum-vt pivotal u.s. food and drug administration (“fda”) investigational device exemption (“ide”) study evaluating the company's vclastm cryoablation system (“vclas” or “vclas system”) for ablation of monomorphic ventricular tachycard.
ADGM Ratings Summary
ADGM Quant Ranking